Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab safety extension in cancer pain
NCT00830180Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2009
- Primary completion
- Feb 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of tanezumab in cancer pain, sponsored by Pfizer. Primary endpoints: Brief Pain Inventory-Short Form Average Pain Score at 64 weeks, Brief Pain Inventory-Short Form Worst Pain Score at 64 weeks and 3 more. Started Oct 2009; status: completed.
02
Drugs
tanezumab
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT00830180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00830180.